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Abstract
HIV treatment initiatives have focused on increasing access to antiretroviral therapy (ART). There 
is growing evidence, however, that treatment availability alone is insufficient to stop the epidemic. 
In South Africa, only one third of individuals living with HIV are actually on treatment. Treatment 
refusal has been identified as a phenomenon among people who are asymptomatic, however, 
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factors driving refusal remain poorly understood. We interviewed 50 purposively sampled 
participants who presented for voluntary counseling and testing in Soweto to elicit a broad range 
of detailed perspectives on ART refusal. We then integrated our core findings into an explanatory 
framework. Participants described feeling “too healthy” to start treatment, despite often having a 
diagnosis of AIDS. This subjective view of wellness was framed within the context of treatment 
being reserved for the sick. Taking ART could also lead to unintended disclosure and social 
isolation. These data provide a novel explanatory model of treatment refusal, recognizing 
perceived risks and social costs incurred when disclosing one’s status through treatment initiation. 
Our findings suggest that improving engagement in care for people living with HIV in South 
Africa will require optimizing social integration and connectivity for those who test positive.
Keywords
Antiretroviral refusal; Engagement in care; South Africa; Treatment refusal; Linkage to care; ART 
initiation
Introduction
South Africa holds a unique position globally, having the largest number of people living 
with HIV in the world, estimated at 6.3 million as of 2013 [1]. The country has also been the 
single largest recipient of funding from the President’s Emergency Fund for AIDS Relief 
(PEPFAR), which has helped underwrite the cost of care for 2.5 million South Africans 
currently in treatment [2, 3]. Despite South Africa’s implementation of the world’s largest 
antiretroviral treatment (ART) program [4], only a third of the over 6 million people living 
with HIV are actually in care [5]. Those who do choose to initiate ART often have very low 
CD4+ cell counts and high rates of co-morbidities, such as tuberculosis or other 
opportunistic infections, putting them at exceedingly high risk of early mortality [6]. The 
goal of achieving population-level reductions in the transmission of HIV in South Africa 
will not be achieved until all ART-eligible individuals are actually on treatment [7], and 
people living with HIV no longer wait to start ART until they have symptoms of advanced 
AIDS [6, 8].
There is expanding literature focused on understanding why millions of ART-eligible 
individuals in South Africa are not engaging in care [6, 9–11]. This is particularly relevant in 
light of increasing evidence of the importance of treatment in individuals living with HIV as 
a form of prevention to uninfected partners [12–14]. Now with a shift in funding allocations 
from PEPFAR, and a move towards decentralization of care [15], there is a greater need to 
understand how to engage individuals living with HIV in a timely manner to avoid potential 
treatment delays [2].
We previously identified treatment refusal as an important cause of failure to link to care 
[16]. Our initial findings in a cohort of individuals presenting for testing in Soweto showed 
that 20 % of those who qualified for treatment refused to initiate ART, and the leading 
reason for ART refusal was given as “feeling healthy” (37 %), despite clients having a 
median CD4+ cell count of 110 cells/mm3 and triple the rate of active tuberculosis as seen in 
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non-refusers. Other groups have now recognized the impact of ART refusal on engagement 
in care [11, 17–21].
These early findings suggest that people living with HIV may have a subjective feeling of 
health and wellness that is not intrinsically related to their actual clinical status. 
Understanding factors that drive treatment refusal will help identify at-risk individuals and 
strategies for effective, targeted interventions to improve linkage to HIV treatment and care. 
This research is essential to prevent what may be an early roadblock to “test and treat” 
strategies aimed at improving ART initiation and outcomes by offering immediate ART to 
individuals upon testing positive. We undertook this qualitative study at the site of our prior 
research in Soweto, South Africa to inductively identify reasons for ART refusal from 
patients’ and providers’ perspectives, and develop a comprehensive explanation of why 
patients who presented to an urban voluntary counseling and testing (VCT) center refused to 
initiate treatment.
Methods
Study Design and Overview
We performed a qualitative, patient and provider focused study using semi-structured 
interview guides. Our goal was to understand why adults who presented for testing and 
learned they were HIV positive and eligible for ART, ultimately refused to initiate 
treatment. Qualitative research allowed us to gain a deeper conceptual understanding of an 
under-studied phenomenon, and provide a basis for developing our explanatory model of 
ART refusal.
Study Site
Zazi Testing Center is a VCT center affiliated with the Perinatal HIV Research Unit and 
Chris Hani Baragwanath Hospital in Soweto, South Africa. Baragwanath is third largest 
hospital in the world, serving the entire population of Soweto [22]. Individuals presenting 
for VCT sign a consent form, have blood drawn, and receive a rapid HIV test. 
Approximately 35 % of clients test positive for HIV. Those who test positive are asked to 
return 1 week later for CD4+ results and referred for treatment as appropriate. The current 
South African Antiretroviral Treatment Guidelines recommend treatment for any individuals 
whose CD4+ count ≤350 cells/mm3 irrespective of WHO clinical stage, or anyone with 
tuberculosis or with WHO stage 3 or 4 irrespective of CD4+ count [23]. We chose this VCT 
clinic because it was the site of our prior research identifying ART refusal, and we felt it 
would provide the most focused understanding of this phenomenon.
Sampling and Recruitment
We used a purposive sampling strategy to select HIV positive adults who presented for VCT 
and were found to be treatment-eligible [24]. Our recruitment strategy was informed by 
research literature showing a range of treatment-related decision-making among adults 
accessing HIV testing in sub-Saharan Africa [25], and our understanding of clients 
presenting for testing at Zazi. Our goal was to represent a comprehensive spectrum of 
decision-making. To this end, we defined the following four groups: “Sustained refusers” 
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were individuals who declined ART after learning they were eligible for treatment, and 
chose not to initiate ART for at least 6 months after testing; “False acceptors” initially 
agreed to start treatment, but failed to present for care within at least 6 months after learning 
of their treatment eligibility; “Initial refusers” declined ART when counseled at testing, but 
ultimately entered care within 6 months; and “True acceptors” were individuals who agreed 
to start ART at testing, and who shortly thereafter presented for care. Our purposive 
sampling strategy is represented schematically in Fig. 1.
Additionally, we interviewed health-service providers who worked at the testing center or 
the PEPFAR-funded treatment center, where most patients were referred, to gain insight into 
provider and delivery-level factors related to treatment refusal among adults who presented 
for testing. Service providers included counselors and social workers who delivered test 
results, as well as treatment providers. For this study, we chose to recruit a total of 50 
participants in order to reach saturation in each subgroup.
Eligibility Criteria
ART decision-makers eligible for this study were: (1) age >18 years at the time of 
enrollment, (2) presenting for VCT at Zazi, (3) willing to have blood drawn for HIV testing 
and CD4+ count, (4) tested positive for HIV and found to be eligible for ART based on 
CD4+ criteria (CD4+ count ≤350 cells/mm3), (5) residents of Soweto, and (6) willing and 
able to give informed consent. Children and pregnant women were excluded, since they 
were enrolled in a separate HIV care program, which included more aggressive follow-up 
and linkage to care procedures than would be standard for routine adult care.
Eligibility criteria for medical and social-service providers included: (1) age >18 years, (2) 
direct contact with clients presenting for VCT or treatment, and (3) willing and able to give 
informed consent. Language spoken by the participant was not an exclusion criterion for this 
study.
Informed Consent
We designed the informed consent procedure for this study to maximize understanding of 
potential risks. To insure correct use of language, all consent forms were translated into Zulu 
and Sesotho, and back translated into English. In addition, the research assistant (RA) read 
consent forms aloud to participants. After reading the consent forms, she requested 
participants summarize the study and explain the reasons why they wanted to participate, 
prior to seeking a signature. Individuals were provided with information on how to contact 
the study staff to report adverse events or other concerns associated with the study.
As part of the informed consent process, participants were informed of how confidentiality 
of participation would be insured. Specifically, all data were coded by subject number. 
Paper copies of data were kept in locked cabinets and only provided to study personnel. 
Electronic data were de-identified and were stored in a secure, password protected site, only 
available to study staff. Interviewers and support staff were trained on procedures for 
maintaining privacy and signed a pledge of confidentiality. This study was approved by 
Partners Healthcare Institutional Review Board, Boston, MA and University of 
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Witwatersrand Human Research Ethics Committee, Johannesburg, South Africa in October 
2011. All study participants provided written informed consent.
Data Collection and Preparation
Semi-structured, in-depth interviews, in which questions were standardized but open-ended, 
were performed with participants between April 2012 and April 2013. All interviews took 
place in a private location at the testing center, and lasted approximately 60–90 min. Topics 
included:
1. Beliefs and experiences involving testing.
2. Experiences of learning one’s HIV status and qualifying for ART.
3. Beliefs regarding ART efficacy, side-effects, and the importance of adherence.
In addition to the standardized questions, we explored areas participants identified as 
relevant to their decision-making, including: religion and faith, stigma, fate, mental health, 
notions of health and wellness, and structural factors. Interviews were conducted by a 
trained RA in English, Zulu, or Sesotho, based on the choice of the participant. The RA 
underwent a detailed training with the primary author, and was supervised by the second 
author. The senior author, an expert in socio-behavioral research with over 20 years of 
experience performing qualitative research, provided guidance for study design and 
interviewer training.
We pilot-tested the interviews with a small group of eligible individuals in advance of 
recruiting our full sample to insure participants would have a full understanding of the 
questions posed in the interview. Participants for our pilot interview included both providers 
and ART-eligible individuals. The pilot test involved using our semi-structured interview 
guide to interview participants. We gauged evidence of comprehension through a dialogue 
with the participant after the interview, as well as a review of transcripts by two authors 
(ITK and GT). All interviews were audio-recorded with permission, and were transcribed 
and translated to English. All transcripts were reviewed for quality by ITK, GT, and KR
Data Analysis
The goal of the analysis was to develop an explanatory model of treatment refusal based on 
participants’ reasons for accepting or declining ART treatment. Using a category 
construction approach, we began our inductive analysis with a detailed review of all the 
transcripts to identify factors related to ART refusal. We used open coding and memoing for 
our initial evaluation of the transcripts, in which interview data were repeatedly reviewed 
line by line to identify sections of text related to treatment decision-making [26]. We then 
moved into a deductive phase of coding, referred to as descriptive coding. For this phase, we 
were guided by our research question, and used QSR International’s NVivo 9 software to aid 
in organizing categories. We assigned labels to each category, and identified illustrative 
quotes from interview transcripts. We ensured trustworthiness of the data by having two 
authors participate in this process (ITK, KR).
We used the same process of data analysis for healthcare providers and adult VCT 
participants. Once we had identified our categories, we re-examined our data and developed 
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broader concepts linking these categories. We ultimately developed an explanatory model of 




Ninety-nine individuals were identified as eligible to participate in the study upon review of 
clinic files, and 50 agreed to participate and were consented (51 %). We interviewed 43 
ART-eligible adults (“patients”) presenting for testing at Zazi and 7 service providers. Of 
the 43 patients, 21 were women and 22 were men. Twelve were sustained refusers, 11 were 
false acceptors, 5 were initial refusers, and 15 were true acceptors. Of the seven care 
providers, three were women and four were men. Table 1 provides a summary of participant 
demographics.
Risks Perceived in Starting Treatment
Participants who refused to initiate treatment framed their concerns in a context of costs or 
risks associated with starting ART. These risks were categorized as follows.
Losing Health or Beauty—Participants who refused to start treatment often framed 
decisions related to their health and well-being. Many described feeling “too healthy” in the 
moment of decision-making to consider ART initiation (see Table 2, Quote 1). Being 
“healthy” and “beautiful” off of medication was often juxtaposed against visual and 
physiologic side-effects associated with being on certain types of treatment. Starting 
treatment was often described in graphic terminology related to body dysmorphic syndromes 
(“They change your shape, you will have a huge stomach and your arms look like weight 
lifters, and you will be ugly and dark in complexion”), and a decline in physical and mental 
health (“These tablets change people – they become dark and have nightmares and lose their 
mind”). Others associated starting treatment with a decline in health (“I was fine all along, 
but once I started the treatment, then I fell ill”) and a feeling of “heaviness” associated with 
lethargy, weakness, and general malaise.
Stigma Associated with Disclosure—Participants recounted stories of both 
internalized shame they felt living with HIV, and externalized stigma they experienced in 
their community. Often, participants’ views on being physically disfigured or mentally 
altered on medication compounded self-defeating beliefs, leading to demoralization and a 
desire to conceal one’s status, and not be seen in clinic (see Table 2, Quote 2). Terms such 
as “trackers” or “starters” were used to refer to people who initiated treatment, or continued 
on treatment, and were framed as being derogatory by participants. The mode of HIV 
acquisition often compounded participants’ internalized stigma (see Table 2, Quote 3). The 
need to stay integrated into one’s community, and the fear of social isolation that would 
result from an HIV diagnosis, often led participants to refuse to initiate treatment in order to 
avoid disclosure.
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Increased Financial Burdens—Starting treatment was often viewed as an 
insurmountable challenge in a life already burdened with an inability to meet the basic needs 
of one’s family (see Table 2, Quote 4). Shame and stigma were often closely linked with 
poverty and it associated stressors (including food insecurity, unstable housing, and limited 
access to transportation to clinic). In poor communities, where neighbors often lived in close 
proximity to each other, participants often reported feeling ashamed and ultimately more 
stigmatized by the public nature of unwanted disclosures due to taking their medications. In 
addition, unstable housing often led participants to fear initiating treatment due to concerns 
about their ability to adhere (see Table 2, Quote 5).
Religious Mores—Participants described faith and God as guiding forces that informed 
decision-making. Participants who started treatment discussed how they believed God was a 
“healer,” but that starting medication was necessary since they were “of flesh and earth,” 
and that God could only heal “if you take your medication.” Conversely, those who chose 
not to initiate treatment also invoked spirituality and faith as a reason not to need treatment 
(see Table 2, Quote 6). Religious mores that centered on morality and a strong belief in God 
as a provider and healer were commonly invoked. While certain congregations appeared to 
support initiating treatment in the setting of a new HIV diagnosis, many participants 
discussed God as the larger force, and that HIV could be considered “a punishment” that 
only God has the power to cure.
Role of Traditional Healers and Alternative Therapies—Those participants who felt 
medications were associated with being sick, often used herbs and sought the counsel of 
traditional healers instead (see Table 2, Quote 7). Both accepters and refusers sought out 
“immuno-boosters” in the forms of vitamins, and other supplements. These were often 
recommended by friends and family members, either as a way to enhance treatment, or as a 
substitute for it (see Table 2, Quote 8). “Traditional medications”, prescribed by “witch 
doctors,” were often referenced as being a cure-all, and being a more natural form of 
therapy.
Protective Factors Offsetting Risks of Starting Treatment
Participants, particularly those who were willing to start treatment, identified multiple 
sources of support that offset the risks associated with treatment initiation.
Social Support—Participants who described having strong social support from family, 
allowing them to disclose their status, often were able to mitigate the challenges associated 
with starting treatment (see Table 2, Quote 9). This support was characterized as providing a 
sense of humanity (“I felt like I was human after all”) and a buffer against normative 
stigmatizing beliefs (see Table 2, Quote 10). Conversely, treatment refusers reported 
wishing for a community support system to allow them to discuss their concerns about their 
diagnosis and treatment (see Table 2, Quote 11).
Coping and Resilience—Coping emerged as a means by which participants attempted to 
manage stigma and move beyond perceived risks of starting treatment. Those who exhibited 
resilience in the face of a new HIV diagnosis often invoked their desire to live for others as a 
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reason to overcome concerns about starting treatment (see Table 2, Quote 12). Many 
participants described living with adversity related to poverty, food insecurity, violence, and 
the stressors associated with volatile relationships or raising children alone, and called upon 
these inherent coping skills in order to initiate treatment (see Table 2, Quote 13). Ultimately, 
adaptive coping strategies that enabled participants to gain acceptance of their diagnosis 
mitigated the perceived risks associated with treatment initiation.
Positive Messages from Government or Media—Participants described ubiquitous 
HIV educational messaging coming from many sources—most notably the South Africa 
Government, and media, through educational soap operas and other forms of entertainment 
(see Table 2, Quote 14). Real life experiences of media personalities living with HIV 
provided messages on how to overcome concerns about starting treatment (see Table 2, 
Quote 15). Others who refused to initiate treatment felt less of a desire to engage in the 
messaging being presented (see Table 2, Quote 16).
Role of Healthcare Providers
Healthcare providers had the potential to moderate the risk of ART refusal by creating an 
environment that provided compassionate care for patients who were concerned about 
initiating treatment. Specifically, a strong therapeutic alliance with providers could establish 
a refuge from HIV-associated stigma, and instill an understanding of the importance of ART 
initiation. One provider described her encounter with a patient who refused to initiate ART 
because she was concerned about the potentially lethal effects of starting medication (see 
Table 2, Quote 17). Conversely, healthcare providers also recognized that clinic staff could 
contribute to patients’ sense of isolation, and feeling stigmatized (see Table 2, Quote 18).
Explanatory Model of Treatment Refusal
To integrate our core findings, we developed an explanatory model for understanding 
treatment refusal. One can best understand our model within a larger context of risk 
perception, which posits that people tend to make decisions about risks based on affect, 
stigma, or fear, and in general, are highly loss averse [27]. For individuals who choose not to 
initiate treatment, the perceived risk of starting treatment may ultimately outweigh the 
known life-saving benefits of being on medication.
Risk is embedded in an optimistic vision of one’s general health and well-being off of ART, 
and in concerns about the harmful effects of being on medication. These concerns may be 
anchored in the knowledge that many prior medications made available to people living with 
HIV were known to have disfiguring side-effects, leading to the possibility of an unwanted 
disclosure of one’s HIV-status. In communities where disclosure could lead to social 
isolation, starting treatment could be perceived as disrupting the fragile balance in which 
many people are living. Therefore in this context, avoiding treatment may be considered a 
safer alternative than initiating ART. Conversely, individuals who are able to draw upon 
social support to minimize the harmful effects of life stressors are able to capitalize on their 
inherent resilience, and overcome fears related to starting ART. These findings support a 
broader more subjective interpretation of perceived barriers to treatment initiation that 
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recognizes both the importance of social support and its impact on affective and cognitive 
judgments [28].
Discussion
This qualitative study provides a novel understanding of why treatment-eligible adults may 
choose not to initiate ART. In our explanatory model, the decision to refuse treatment is 
based on an optimistic view of one’s own health, and a belief that starting medications can 
be inherently risky due to potentially disfiguring side effects, resulting in an unwanted 
disclosure and social isolation. This may lead to seemingly irrational choices to avoid 
detection until disease progression renders further concealment impossible.
Central to this model is the meaning of ART initiation for participants, and the common 
belief that people living with HIV initiate treatment when they are sick, instead of starting it 
while healthy. As such, participants experience starting treatment as an acknowledgement of 
poor health, and potentially their own mortality. Fears of side-effects associated with ART, 
stigma from being identified as “sick”, and concerns about one’s own inability to adhere to 
treatment often augment the perceived risks inherent to treatment initiation [29, 30]. Prior 
qualitative research in South Africa has similarly shown that ART has often been viewed as 
signifying AIDS and approaching mortality [11].
In this context, social support proves critical to enhancing participants’ ability to cope with 
the life changes that are required to overcome concerns related to ART side-effects, 
internalized and externalized stigma, potentially increased financial burdens, and the lure of 
seemingly safer alternative therapies. While little research has focused on the impact of 
social connectivity and adaptive coping on decision-making prior to ART initiation, social 
integration has been recognized as a core component of treatment adherence in resource-
limited settings [31–33]. The importance of social support and integration are particularly 
salient in settings of extreme poverty where treatment barriers are highly prevalent [34–37] 
and social ties may be essential for survival [33, 38, 39], ultimately allowing people living 
with HIV to cope with internalized stigma [40].
People with early-stage disease are particularly at risk. First, they may not perceive the need 
for treatment because they have not yet experienced loss of physical function, a powerful 
motivator for behavior change [41]. Second, due to the stigmatized status of HIV infection 
in many resource-limited settings [40, 42–44], people living with HIV with full functional 
status might have less motivation to disclose their status [45–48]. Nam et al. also found that 
ill patients experience faster acceptance of their HIV status, which facilitates HIV disclosure 
and activates their social support network [49]. Green and Wagner found that HIV 
disclosure is closely associated with the degree of tangible support HIV+ people receive 
from their network [50]. Taken together, these findings suggest that people with early-stage 
disease might not disclose their HIV status, might not activate their social ties, and might not 
mobilize social support to overcome the common structural barriers to HIV care in resource-
limited settings; this could result in sub-optimal engagement in care and failure to initiate 
ART.
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In addition, socioeconomic barriers to care may impede engagement in care, as has been 
described previously, despite the widespread availability of free treatment through PEPFAR 
and the Department of Health clinics [51]. These findings suggest that existing ART 
programs may be more successful if coupled with economic incentives to initiate and adhere 
to treatment, since this may provide economic stability that is necessary for treatment 
initiation and retention in care.
Our study has several limitations. First, within our purposively sampled targeted groups, we 
were limited to a convenience sample of patients who could be located and were willing to 
be interviewed; thus, our data may not capture the reasons for ART refusal among people 
who could not be located, or who were not willing to be interviewed. In addition, our data 
may not capture reasons for ART refusal in other locations in South Africa. Future studies 
should examine reasons for treatment refusal at multiple sites.
Despite these limitations, our study has many strengths. First, while treatment decisions 
have previously been dichotomized into “acceptance” or “refusal,” we found evidence for a 
spectrum of decision-making, and were able to interview participants in each category. In 
addition, the explanatory model that emerged from our qualitative research has several 
important implications for the public health strategies now being explored in areas of sub-
Saharan Africa with high-HIV prevalence rates (e.g., universal voluntary testing with an 
immediate “test-and-treat” strategy [52, 53]) by providing a framework for understanding 
how and when people may delay starting treatment, despite optimal access to care. Finally, 
our results revealed several modifiable factors that could be targeted in future interventions 
to increase ART initiation, including: economic incentives, peer-based social support 
programs, and further education about the side-effects of ARTs currently available in South 
Africa.
Conclusion
Optimizing engagement and long-term retention of adults living with HIV requires 
understanding decision-making in the pre-ART period. This qualitative study in Soweto, 
South Africa, provides a novel explanatory model of treatment refusal, which recognizes the 
relative importance of perceived risks associated with starting treatment in otherwise 
asymptomatic adults. These risks relate to the social costs incurred when disclosing one’s 
status in a community where being identified as “sick” from HIV may potentially be the 
tipping point in a life that may hang in a fragile balance. Conversely, social integration and 
connectivity may provide those who test positive with sufficient support to promote 
effective coping strategies and overcome fears related to treatment initiation. Future research 
should test interventions that target modifiable factors identified through this study to 
optimize engagement in care.
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Table 1
Characteristics of cohort
Characteristics n or mean % or SD
Male sex 21 48.8
Age (years) 33.8 6.5
Nationality, South African 41 95.3
Marital status, married/co-habitating 8 18.6
Marital status, divorced/single 35 81.4
Ethnicity, Zulu 20 46.5
Ethnicity, Sesotho 9 20.9
Employed 18 41.9
Unemployed/student 25 58.2
Education, some high school or less 15 34.9
Education, matriculated or higher education 26 60.5
Residence, brick house or family house 28 65.2
Residence, shack, back room, or hostel 14 32.6
Residence, owner 24 55.8
Residence, rental 18 41.9
Self-referral 36 83.7
Referral from local clinic or other 7 16.3
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Table 2
Categories identified by participants regarding the risks and protective factors associated with ART initiation
Categories Gender Treatment decision Representative quotation
Risk
Losing health or beauty
F Sustained refuser QUOTE 1: “I [feel] very healthy. I found out in 2004 that I am HIV 
positive […] I was not understanding negative and positive. They said, 
‘You are HIV positive,’ and I said, ‘I am not HIV positive.’ […] I told 
myself that I am beautiful and they say I am HIV positive. Are they sick? I 
said, “No, they are mad. How can they say that?” I am very healthy”
Risk
Stigma associated with 
disclosure
F Initial refuser QUOTE 2: “In a rural area, it’s a small place even though you trust the 
nurses and stuff like that. People who are in the clinic, they know that you 
go to that door when you are HIV positive. You come in this way, so they 
will notice, “Wow, she is also HIV positive.” So they will start talking, I 
have got my ex’s in this area”
F Initial refuser QUOTE 3: “I think the main thing is that you get it by having sex. That is 
the problem… so people think that when you are HIV positive you have 
been sleeping around, maybe you have been selling your body or 
something… you have been careless with your body. So people are scared 
that they are going to be labeled as a person who has been so selfish as 
someone who has been sleeping around. That’s why people are so scared to 
be known as being HIV positive”
Risk
Increased financial burdens
F False acceptor QUOTE 4: “I even told [the counselor] that they had referred me to start 
taking ARV’s, but my problem is that sometimes I do not have food to eat 
at all. How can I take [ARVs] when I don’t have food to eat? So now that 
means that I will default, but if I knew that I had money then I would take 
them”
F False acceptor QUOTE 5: “To tell you the truth, where I am currently staying, it’s 
difficult for me, to the point that there was an argument this past Saturday 
and…they told me I should go and look for a place to rent. Alright, I don’t 
buy food because I don’t work and they also complained about that. So you 
see, this thing is emotionally hurting me… I was even saying that if I was 
working, I would move out and live elsewhere and I would not go to bed on 
an empty stomach… I would be able to take my tablets… I don’t deny that 
I need to take ARV’s, but I am looking at my living conditions, and the fact 
that I might take them and then default”
Risk
Religious mores
M Initial refuser QUOTE 6: “So, when I went to church with my brother, they discussed 
HIV as a disease, but there was an element to say that it is for promiscuous 
people and they push prayer more than they push ARVs… For people who 
are strong believers, [I believe] they can really be cured. I think with God - 
what is impossible with man- is possible with God”
Risk
Role of traditional healers 
and alternative therapies
M Sustained refuser QUOTE 7: “I don’t use ART. I use the traditional herbs that I am used to, 
like ‘ingwe’ [an herbal remedy known as an immune booster]. It also tries 
to kill the virus. It also helps to maintain a healthy life and not lose weight. 
It boosts the immune system”
M Sustained refuser QUOTE 8: “My mom went and brought me some medication that they sell 
for around three hundreds or four hundred rand at Clicks [a department 
store] - The ones that boost the immune system. I took them for about a 
week and I felt that they were not helping me. I told her that I don’t want 
medication…My father told me to keep on taking the medication…”
Protective
Social support
M True acceptor QUOTE 9:
Interviewer: “Who exactly have you told in your family?”
Participant: “I told everyone, I first told my brother, and then my sister 
when I got home. I then called my Aunt. They said that I should accept [my 
HIV diagnosis] and take treatment”
Interviewer: “Oh they told you that as long as you take treatment you will 
be okay?”
Participant: “Yes, and there is nothing discriminating that they do since 
they know, like not allowing me to do certain things”
M True acceptor QUOTE 10: “I come from a very supportive family, when you make 
mistakes they are supportive. And with other families, when [they learn you 
are HIV positive] they start to exclude you and tell neighbors, ‘Don’t see 
him like this. He has Z3 [slang reference for the three letters in the HIV 
acronym]- he has HIV.’ You get what I’m saying?”
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Categories Gender Treatment decision Representative quotation
F Sustained refuser QUOTE 11: “I would like to meet some people who are in the same 
situation [living with HIV] - like support groups, stuff like that, so that I 
could get courage. And then I can see that I am not alone in that situation”
Protective
Coping and resilience
F Initial refuser QUOTE 12: “In rural areas, we have fields where there is no one. I went 
there and I wrote a suicidal letter. It was addressed to my grandmother and 
my aunts. But then I thought of people who love me. I thought my teacher 
wouldn’t like this. She wouldn’t be proud of me, because she knows that I 
am a fighter. I am a hard- worker, and if I do this she will be disappointed. I 
just cried and cried and then I said, let me just pull myself together. I lost 
my mother. I got shot and I survived. So why am not going to survive this 
HIV thing?”
F True acceptor QUOTE 13: “When I found out that I was HIV positive - you blame 
yourself…You feel like is your fault. Okay sometimes it is not your fault. 
Like myself I was married. My husband was gathering around with every 
girlfriend that he found. So I relied on myself saying, if I am faced with 
this, I am going to take whatever is coming at me. That is why today, I 
know how to stand up for myself. I am facing it…Whatever storm comes 
my way, I can take it”
Protective
Positive messages from 
government or media
F True acceptor QUOTE 14: Interviewer: “What kind of information have you heard from 
our government about ARV’s?”
Participant: “It’s that you have to start taking treatment with a CD4 of 350.”
Interviewer: “Do you think that the media is also involved in terms of 
talking about ARV’s?”
Participant: “Yes they are. I think that sometimes people need repetition. 
When you hear something over and over again, even if you don’t want to 
listen, you end up listening. It’s in your face and you can’t run away from 
it. Things like Soul City [a non-governmental organization that produces a 
television show focused on living with HIV in a poor community in South 
Africa] - everything is educating these days”
M True acceptor QUOTE 15: “So I see that the HIV treatment is good, especially when I 
look at the statistics on TV. I can see that the babies are even protected, and 
I see that the rate is going down, and you can live a long time [on 
treatment]. Because there was this white guy who disclosed his status on 
TV, and said that he has been infected for 25 years. That’s when I became 
motivated and encouraged [to start ART]”
M Sustained refuser QUOTE 16: “The media is always talking about antiretrovirals all the time. 
They tell us to take ARV’s so that we will live. Wherever you go, there are 
these people who are doing HIV testing on the streets, maybe on the radio 
and TV. They are always talking about antiretrovirals. I will not be 
influenced by the media. If I see something in my ear, hands, mouth or my 
genital area – it is only then that I will consider going to the clinic to initiate 
taking ARV’s, because by then I would be in a bad condition”
Role of healthcare providers QUOTE 17: “The client was afraid to take treatment because [she 
believed] her sister was killed by treatment. I asked how the sister was 
killed by treatment and the client said that by the time the sister took 
treatment, she was very sick, and then she passed on. [The sister] had 
delayed, and refused. So it is because the sister passed away after starting 
ARV treatment [that the client now refused]. So I asked if the client found 
out if it is true that treatment can kill, and the client said the sister’s death 
was the evidence. So, I explained to the client about how the treatment 
works in a human body, and maybe the sister started it late… Since she was 
sick, helpless and had HIV symptoms, that is why she passed away. I 
advised the client to start treatment because of her low CD4 count”
QUOTE 18: “There was a client who did not want to take treatment 
because of the bad attitude by the clinic staff. The client was not given any 
explanation before testing for HIV, and was told to start taking treatment 
because it is a matter of life and death, so there was no one to explain why 
the client has to take ARV’s. The clients were being shouted at for not 
using condoms. They were told that is why they got infected. So the clients 
would not take treatment because of the bad attitude they got”
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